Rethinking Neurodegenerative Disease Treatment: Target Multiple Pathological Proteins, Not Just One
Nearly all major neurodegenerative diseases – from Alzheimer’s to Parkinson’s – are defined and diagnosed by the presence of one of four proteins that have gone rogue: tau, amyloid-beta (Aβ), alpha-synuclein (α-syn), or TDP-43. As such, investigational drugs and studies aimed at preventing or slowing the disease often hone in on just one of these respective proteins. However, targeting multiple proteins—known as “proteinopathies”—at once may be the real key, according to a recent study published in Brain by Penn Medicine researchers.
IOA IN THE NEWS
07/27/18Finding a cure for Alzheimer’s disease has proved elusive. The drugs currently on the market only manage the symptoms of…
07/06/18Proteinopathies, the misfolded proteins responsible for neuron deaths, have a claim to fame when it comes to rare neurodegenerative…
03/06/18The epigenomic landscape of Alzheimer’s disease brains is profiled in a new study from from the Perelman School of Medicine.
Join the nearly 200 Institute on Aging Fellows and Associate Fellows and experience robust collaborative opportunities in aging at Penn, for funding opportunity alerts, pilot research grant opportunities, and updates on IOA activities.
FEATURED VIDEOVideo Archive
Penn Medicine's 5K for the IOA and the Memory Mile Walk
Save the date:
Sunday, September 23, 2018
8:00am @ Penn Park
MAKE A GIFT
Support aging-related research, education, and care at the IOA!
THE SCIENCE OF AGING NEWSLETTER
In this issue:
- Former PA Governor Rendell treated for Parkinson's at Penn
- Avoiding Heat Stress in High Summer Temps
- Rethinking Neurodegenerative Disease Treatment
… and more!
Download the 2018 Summer Newsletter here
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team.